Treatment of valproate-induced hyperammonemia [7]

Journal of the American Geriatrics Society

Volumn 53, Issue 6, 2005, Pages 1080-

  Stewart, Jonathan T ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b Bay Pines VA Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA; LACTULOSE; OLANZAPINE; VALPROIC ACID; TRANQUILIZER;

AGED; AMMONIA BLOOD LEVEL; ANAMNESIS; CASE REPORT; HUMAN; HYPERAMMONEMIA; LETTER; MALE; PROTEIN RESTRICTION; SCHIZOPHRENIA; BLOOD; CHEMICALLY INDUCED DISORDER; TREATMENT OUTCOME;

AGED; ANTIMANIC AGENTS; HUMANS; HYPERAMMONEMIA; MALE; SCHIZOPHRENIA; TREATMENT OUTCOME; VALPROIC ACID;

EID: 23444447297     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2005.53338_7.x     Document Type: Letter

References (6)

1. Murphy JV, Marquardt K. Asymptomatic hyperammonemia in patients receiving valproic acid. Arch Neurol 1982;39:591-592.
2. Williams CA, Tiefenbach S, McReynolds JW. Valproic acid-induced hyperammonemia in mentally retarded adults. Neurology 1984;34:550-553.
3. Raja M, Azzoni A. Valproate-induced hyperammonaemia. J Clin Psychopharmacol 2002;22:631-633.
4. Barrueto F, Hack JB. Hyperammonemia and coma without hepatic dysfunction induced by valproate therapy. Acad Emerg Med 2001;8:999-1001.
5. Feil D, Chuang K, Sultzer DL. Valproate-induced hyperammonemia as a cause of altered mental status. Am J Geriatr Psychiatry 2002;10:476-478.
6. Kane RE, Kotagel S, Bacon BR et al. Valproate use associated with persistent hyperammonemia and mitochondrial injury in a child with Down's syndrome, J Pediatr Gastroenterol Nutr 1992;14:223-227.